Immunogenicity of infliximab and adalimumab
Sign Up to like & getrecommendations! Published in 2019 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2019.1602117
Abstract: TNF-α inhibitors have demonstrated efficacy both as monotherapy and in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of chronic inflammatory immune-mediated diseases [1,2]. TNF-α may promote progression of endothelial dysfunction and, thus, of… read more here.
Keywords: immunogenicity infliximab; infliximab adalimumab;